Written on: March 31, 2021 by SprayTM
Newly-formed company RxPack (pronounced R-x-Pack) will include complementary product lines from LINDAL Group and Coster Group for spray packaging solutions for pharmaceutical applications. RxPack will offer pulmonary inhalation devices, such as aerosol MDIs and nasal pumps, as well as other aerosol and dispensing solutions for the regulated and non-regulated pharmaceutical sectors.
RxPack’s packaging solutions will be supplemented with the corresponding aerosol filling machinery for the pharmaceutical sector. The new company will operate from the current facility of LINDAL’s pharmaceutical business in Oggiono, north of Milan in Italy. It is expected to enter business by the end of this 2021, after the approval from the relevant authorities. Coster and LINDAL will each have an equal share in RxPack.
“RxPack is being established to take our pharmaceutical business to the next level and to create momentum in the pharmaceutical packaging sector,” said Katharina Lilienthal, Chairwoman of the Board of LINDAL and representative of the LINDAL shareholder family.
“With its distinctive product portfolio and its strong financial resources, RxPack is ideally positioned to grow in the non-regulated sector and to enter the highly attractive regulated sector,” Lilienthal continued.
“Our goal is to create a new strong player in the field of packaging solutions for pharmaceutical applications,” explained Martina Segatta, Chair of the Board and majority shareholder of Coster.
“RxPack has the expertise, the products and the financial strength to provide our pharmaceutical customers with innovative solutions that significantly improve the health and lives of sick people. With RxPack, we’ve created a powerful setup dedicated to the pharmaceutical sector that will enable us to serve this mission excellently and make the most of the opportunities in this sector.”
RxPack will be able to use the existing Oggiono production facility already focused on the pharmaceutical business. The site offers working and production conditions including the required cleanrooms and laboratories and the opportunity to build further capabilities to serve the pharmaceutical sector. RxPack will start its operations with approximately 60 employees, all of whom have previously worked in the pharmaceutical business. RxPack will also hire additional industry experts to further strengthen the organization.
An initial investment of €4 million has been allocated for upgrading and extending clean room manufacturing capabilities. Thereafter, further investments are planned to drive innovation and growth.
Outside of RxPack, LINDAL and Coster are competitors in numerous areas and will remain so. RxPack will therefore operate as a stand-alone entity that is completely independent from the two groups.
Bag-on-Valve (BOV) products manufactured by Coster and LINDAL will not be included in RxPack, as they are based on a different technology that is deployed in applications not only for the pharmaceutical industry, but also for many other sectors. LINDAL and Coster will both continue to offer BOV products, also for the pharmaceutical sector, and remain strong competitors in this area.
To ensure its independence, RxPack will have a fully autonomous organization with corresponding governance and separate facilities. The facility in Oggiono will be exclusively dedicated to RxPack. All other non-pharmaceutical activities at this location will therefore be relocated to other LINDAL facilities during a carefully managed transition period.
For more information: email@example.com